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Summary of: Hancock MJ, Maher CG, Latimer J, McLachlan 
AJ, Cooper CW, Day RO, Spindler MF, McAuley JH (2007) 
Assessment of diclofenac or spinal manipulative therapy, or 
both, in addition to recommended first-line treatment for 
acute low back pain: a randomised controlled trial. The 
Lancet 370: 1638–1643. [Prepared by Julia Hush, CAP 
Editor.]
Question: Does the addition of non-steroidal anti-
inflammatory drugs (NSAIDs) or spinal manipulative therapy 
(SMT), or both, result in faster recovery for patients with 
acute low back pain receiving recommended first-line care 
from a general practitioner? Design: Randomised controlled 
trial with factorial randomisation into 4 treatment arms. The 
study used concealed allocation, blinding of participants 
(who assessed most outcomes), blinding of prescribers of 
one intervention, and intention-to-treat analysis. Setting: 
Community-based study involving 40 general medical 
practitioners and 15 physiotherapists in private clinics in 
Sydney, Australia. Participants: 240 patients with low back 
pain (with or without leg pain) of less than 6 weeks duration 
were included. Patients with suspected serious spinal 
pathology, nerve root compromise, or contraindications to 
SMT, NSAIDs or paracetamol were excluded. Interventions: 
All participants were given baseline care as recommended 
in current clinical guidelines. This consisted of advice by the 
general practitioner (remain active, avoid bed rest, expect 
recovery) and the recommendation to take paracetamol (1g 
four times daily) until recovery, or a maximum of 4 weeks. 
Within 2 days of the GP visit, participants were randomly 
allocated to a one of 4 treatments: diclofenac (NSAID) 50 
mg twice daily and placebo SMT; SMT and placebo drug; 
diclofenac 50 mg twice daily and SMT; or double placebo. 
The placebo NSAID was an inactive tablet with identical 
size, shape, and colour. The placebo SMT was detuned, 
pulsed ultrasound, providing matched treatment time and 
therapist contact. Participants were not informed whether 
their group allocation was active or placebo for either 
intervention. Outcomes: The primary outcome was days to 
recovery from pain assessed by survival curves. Recovery 
from pain was defined in two ways: the first pain-free day 
and the first day of a seven-day, pain-free period. Results: 
When recovery was defined as the first pain-free day, the 
rates of recovery for all participants in the trial were high: 
99% of participants either recovered or were censored 12 
weeks after randomisation. The addition of NSAIDs or 
SMT, or both, gave no additional clinically-worthwhile 
benefit to recovery rates (diclofenac hazard ratio 1.09, 95% 
CI 0.84 to 1.42; SMT hazard ratio 1.01, 95% CI 0.77 to 1.31). 
Similar results were obtained when the alternate definition 
of recovery was used. Conclusion: This study provides 
robust evidence that recommended primary care of acute 
low back pain results in rapid recovery, with no further 
benefit provided by NSAIDs or SMT.
Manipulative therapy or NSAIDS do not provide additional 
benefit to quality baseline care for acute back pain
Synopsis
Commentary
This high quality randomised controlled trial (RCT) 
addressing a general practitioner (GP) clinical question 
(refer or don’t refer?) reported results that are challenging 
for manual therapists treating people with acute non-
specific low-back pain (ANSLBP). It concluded that people 
with ANSLBP attending a GP who provided guideline-
recommended treatment (advice plus paracetamol) received 
no additional benefit from a physiotherapist providing 
SMT.
There are several issues to consider before drawing 
conclusions about clinical practice from the results of 
this trial. First, participants typically had a pain duration 
of approximately 1 week, so these results do not apply 
to patients with longer lasting pain. Second, the trial’s 
randomisation schedule determined which patients would 
receive manual therapy or not, rather than a clinician’s 
judgement deciding this. Perhaps only some ANSLBP 
patients respond favourably to manual therapy. However, 
there are currently no reliable methods to determine which 
patients will respond to particular treatments (Billis et al 
2007). Third, only 5% of participants received high velocity 
SMT. Although there is no clear evidence that high velocity 
SMT is more effective than mobilisation (Assendelft et al 
2004), proponents of the former will claim that this study 
did not test the effectiveness of this technique. Fourth, 
it would have been interesting to see a ‘GP only’ group. 
Perhaps there is something gained from being referred to a 
physiotherapist, even if the treatment itself is a placebo.
Finally, the question remains, if a patient with ANSLBP 
consults a GP, will guideline-recommended treatment 
be provided? The evidence suggests otherwise and best 
practice is not guaranteed (Buchbinder and Jolley 2007). In 
the Hancock RCT, GPs were given training to deliver best 
care. Perhaps patients in the ‘real world’ would not receive 
this quality care from their GP.
This trial does not bring the world crashing down for 
manual therapists as some press reports have stated, but 
the treatment these therapists provide does need to be 
considered carefully in light of the trial results.
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